Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
04/2005
04/05/2005US6875765 Inhibitors of interleukin-1 beta converting enzyme and other cysteine proteases in the ICE family
04/05/2005US6875736 Methods for identifying RNA binding compounds
04/05/2005US6875612 Expression vector coding proteins for use in the treatment of tumors
04/05/2005US6875599 Enzymatic protein for use in the treatment of inflammation, cancers, cardiovascular, brain, respiratory and crohn's disease
04/05/2005US6875447 Analgesics; pain therapy; administering by injection
04/05/2005CA2339621C 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
03/2005
03/31/2005WO2005028513A2 High-yield method for the production of human antibodies blocking the biological activity of a human cytokine
03/31/2005WO2005028455A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
03/31/2005WO2005028426A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor
03/31/2005WO2005027951A1 Method for controlling angiogenesis in animals
03/31/2005WO2005027944A1 Oral compositions and route of administration for the delivery of a thylakoid extract
03/31/2005WO2005027893A1 HUMAN β-DEFENSIN SECRETION PROMOTER
03/31/2005WO2005027889A1 Visceral pain dulling composition
03/31/2005WO2004108141A3 Bach-o-protein coupled receptor releated methods
03/31/2005WO2004108133A3 Modulators of vr1 receptor
03/31/2005WO2004094379A3 3-phenyl-4- (pyrimidin-2-yl) -6- (piperidin-4-yl) derivatives and related compounds as tnf-alpha and il-1 inhibitors for the treatment of inflammations
03/31/2005WO2004087158A3 Muscarinic m1 receptor agonists for pain management
03/31/2005WO2004032900A8 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
03/31/2005WO2003018756A3 Methods for preparing purified prostaglandin e synthase
03/31/2005WO2002042319A9 2-substituted estrogens as antiangiogenic agents
03/31/2005US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents
03/31/2005US20050070713 Neurokinin antagonist; therapy for central nervous system disorders; psychological disorders; Parkinson's and Huntington's disease
03/31/2005US20050070694 Antagonistic anti-htnfsf13b human antibodies
03/31/2005US20050070692 Anti-interleukin-1 beta analogs
03/31/2005US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders
03/31/2005US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity
03/31/2005US20050070582 For example,1-{[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl}-4-ethylpiperazine or 1-{[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl}piperazine; for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders
03/31/2005US20050070581 such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease
03/31/2005US20050070574 Novel compounds
03/31/2005US20050070572 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies
03/31/2005US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors
03/31/2005US20050070566 Imidazoquinoline derivatives
03/31/2005US20050070558 For example, [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetic acid; useful in preventing mast cell degranulation and therefore useful in treatment of diseases induced by activation of A2b receptor and mast cell activation such as asthma, allergic reactions
03/31/2005US20050070555 Aroyl pyridinones
03/31/2005US20050070549 heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation
03/31/2005US20050070529 Use of type 4 phosphodiesterase inhibitors in myocardial diseases
03/31/2005US20050070527 For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions
03/31/2005US20050070525 Such as 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenyl-methyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2- alpha ]benzimidazol-4(10H)-one
03/31/2005US20050070514 Administering phosphodiesterase 4 inhibitor in combination with beta agonist and an anti-inflammatory steroid
03/31/2005US20050070510 Tetracycline compound of given formula, an antifungal agent such as amphotericin B and a carrier; treating fungal infections
03/31/2005US20050070485 Phenylalanine derivatives
03/31/2005US20050070477 Lung surfactant polypeptide, and at least one inhibitor of a mediator of tissue destruction; for example protease inhibitors; treating inflammatory lung conditions such as asthma, chronic obstructive pulmonary disease
03/31/2005US20050070466 Diagnostic imaging agents; targeting vectors which bind to integrin receptors; bicyclic arginine-glycine-aspartic acid derivatives; stablility; reduced background interference
03/31/2005US20050070459 treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor
03/31/2005US20050069983 Nucleotide sequences coding membrane protein for use in identifying modulator for prevention and treatment of herpes viral infection, cell proliferative and autoimmune disorders
03/31/2005US20050069888 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
03/31/2005US20050069878 Proteins associated with cell growth, differentiation, and death
03/31/2005US20050069877 Protein modification and maintenance polypeptides (PMOD) for use as diagnostic and therapeutic tools in treatment of prevention of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, developmental, epithelial, neurological, and reproductive disorders
03/31/2005US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders.
03/31/2005US20050069595 Antiinflammatory agents; mixture with glucocorticoids; respiratory system disorders; antiarthritic agents
03/31/2005US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
03/31/2005US20050069541 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
03/31/2005CA2539172A1 High-yield method for the production of human antibodies blocking the biological activity of a human cytokine
03/31/2005CA2538760A1 Human .beta.-defensin secretion promoter
03/31/2005CA2538291A1 Substituted sulfonamides
03/31/2005CA2537094A1 Novel adenosine a3 receptor agonists
03/31/2005CA2535208A1 Oral compositions and route of administration for the delivery of a thylakoid extract
03/30/2005EP1518555A1 Analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
03/30/2005EP1518553A2 Use of nitrate ester compounds for treating pain or providing analgesia
03/30/2005EP1518517A2 Drug-delivery endovascular stent and method for treating restenosis
03/30/2005EP1517919A2 Marked peptides having affinity for a phospholipid and uses
03/30/2005EP1517918A2 Peptides having affinity for a phospholipid and uses
03/30/2005EP1517914A2 9-alpha-substituted estratrienes as selectively active estrogen
03/30/2005EP1517912A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
03/30/2005EP1517907A2 Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
03/30/2005EP1517905A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases
03/30/2005EP1517902A2 Lactone compounds, for use as antioxidant agents in pharmaceutical, cosmetic or food compositions
03/30/2005EP1517897A2 Benzimidazole compounds and their use as estrogen agonists/antagonists
03/30/2005EP1517896A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity
03/30/2005EP1517895A1 8-(biaryl) quinoline pde4 inhibitors
03/30/2005EP1517894A1 N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin antagonists and/or serotonin reuptake inhibitors
03/30/2005EP1517889A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors
03/30/2005EP1517694A1 Plant extracts
03/30/2005EP1517693A1 Pharmaceutical compositions
03/30/2005EP1517685A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses
03/30/2005EP1517679A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
03/30/2005EP1517675A1 Composition for treatment of inflammatory disorders
03/30/2005EP1517667A2 Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
03/30/2005EP1438289B1 Indole derivatives as cox ii inhibitors
03/30/2005EP1436007B1 Compounds for use as surfactants
03/30/2005EP1390025B1 Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders
03/30/2005EP1360184B1 Piperidine derivatives as neurokinin 1 antagonists
03/30/2005EP1322350B1 E-ptfe foil impregnated with an encapsulated bioactive substance
03/30/2005EP1250132B1 Ibuprofen containing active agent preparation
03/30/2005EP1242089B1 Use of adatanserin for the treatment of acute neurodegenerative disorders
03/30/2005EP1183361B1 Gene therapy of pulmonary disease
03/30/2005EP1181035B1 Substantially oil-free cyclosporin compositions
03/30/2005EP1105378B1 Quinazoline derivatives
03/30/2005EP1075467B1 Pyrazole derivatives as p-38 map kinase inhibitors
03/30/2005EP0980369B1 Sulfonamides for treatment of endothelin-mediated disorders
03/30/2005CN1602425A Therapeutic and diagnostic uses of antibody specificity profiles
03/30/2005CN1602358A Recombinant fusion proteins and the trimers thereof
03/30/2005CN1602317A Angiopoietin-2 specific binding agents
03/30/2005CN1602311A Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase
03/30/2005CN1602310A Benzothiazoles compound
03/30/2005CN1602307A Substituted 6h-dibenzo[c, h]chromenes as estrogenic agents
03/30/2005CN1602304A Deuterated substituted dihydrofuranones and medicaments containing these compounds
03/30/2005CN1602292A Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists
03/30/2005CN1602199A Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
03/30/2005CN1602191A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
1 ... 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 ... 1272